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Chromatin modulators are emerging as attractive drug targets, given their widespread implication in human
cancers and susceptibility to pharmacological inhibition. Here we establish the histone methyltransferase G9a/
EHMT2 as a selective regulator of fast proliferating myeloid progenitors with no discernible function in
hematopoietic stem cells (HSCs). In mouse models of acute myeloid leukemia (AML), loss of G9a significantly
delays disease progression and reduces leukemia stem cell (LSC) frequency. We connect this function of G9a to its
methyltransferase activity and its interaction with the leukemogenic transcription factor HoxA9 and provide
evidence that primary human AML cells are sensitive to G9A inhibition. Our results highlight a clinical potential
of G9A inhibition as a means to counteract the proliferation and self-renewal of AML cells by attenuating HoxA9-
dependent transcription.
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The involvement of epigenetic regulators like MLL
(Tkachuk et al. 1992), EZH2 (Morin et al. 2010), DNMT3A
(Ley et al. 2010), and TET2 (Delhommeau et al. 2009) in
the pathology of human leukemias has stimulated a great
deal of interest in identifying chromatin-modifying en-
zymes that can be targeted therapeutically (Arrowsmith
et al. 2012; Dawson and Kouzarides 2012). For example, a
catalytic inhibitor of DOT1L interferes with the oncogenic
activity of MLL fusions often found in pediatric leukemias
(Daigle et al. 2011). Furthermore, LSD1/KDM1A inhibi-
tion suppresses acute myeloid leukemia (AML) stem cell
activity (Harris et al. 2012; Schenk et al. 2012), and
disruption of the chromatin binding of Brd4 by a BET
bromodomain inhibitor blocks c-Myc expression and the
proliferation of leukemic cells (Delmore et al. 2011; Zuber
et al. 2011). To date, several inhibitors of histone methyl-
transferases and demethylases have been reported, includ-
ing those that target G9a and GLP with high specificity
(Kubicek et al. 2007; Vedadi et al. 2011; Yuan et al. 2012).
G9a/GLP uniquely catalyze mono- and dimethylation of
histone 3 on Lys9 (H3K9me1/2) (Tachibana et al. 2002,
2005), a highly abundant chromatin mark in mammalian
cells. G9a/GLP take part in a number of corepressor
complexes, and H3K9me2 is enriched at inactive loci
(Barski et al. 2007; Dong et al. 2008) and CpG islands
(Lienert et al. 2011). In addition, G9a can activate tran-
scription at least in part by acting as a cofactor for the
Mediator complex (Chaturvedi et al. 2012). Interestingly,
H3K9me2-enriched domains are mostly devoid of
H3K27me3 mediated by Ezh1/2 (Lienert et al. 2011),
suggesting that G9a/GLP-dependent pathways govern the
expression of genes involved in cell differentiation in
addition to those that are subject to PRC2-dependent
repression. This has been demonstrated in certain contexts,
as G9a mediates T-helper cell diversification (Lehnertz
et al. 2010) and embryonic stem cell (ESC) differentiation
(Feldman et al. 2006). Furthermore, G9A/GLP inhibition
delays the differentiation of human hematopoietic stem
cells (HSCs) ex vivo (Chen et al. 2012), suggesting addi-
tional roles in early hematopoiesis. Despite recent ad-
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vances in delineating biological roles of G9a/GLP, a detailed
characterization of these enzymes during hematopoiesis
has not been reported.
Results
Selective requirement for G9a in hematopoietic
progenitor cells
To confirm the expression of G9a in the hematopoietic
system, we performed quantitative RT–PCR (qRT–PCR)
analyses from FACS-purified hematopoietic subpopula-
tions and detected high expression of G9a in hematopoi-
etic stem and progenitor cells (HSPCs), at levels compara-
ble with mouse ESCs, and the lowest expression in mature
myeloid and lymphoid cells (Supplemental Fig. S1). We
then investigated the biological importance of G9a in the
hematopoietic system using G9afl mice (Fig. 1A; Lehnertz
et al. 2010) crossed with Vav-Cre transgenic mice to obtain
G9a+/fl; Vav-Cre and G9afl/fl; Vav-Cre mice [G9a+/ (Vav)
and G9a/ (Vav), hereafter]. As expected (Stadtfeld and
Graf 2005; Gan et al. 2010), Vav-Cre-mediated excision in
G9a/ (Vav) mice harboring a ROSA26-YFP (R26-YFP) Cre
reporter was specific to hematopoietic cells and fully
penetrant (Supplemental Fig. S2a–c). Consistent with
previous reports (Tachibana et al. 2002, 2005), deletion
of G9a resulted in a characteristic reduction in GLP and
H3K9me2 levels in bone marrow-derived macrophages
(BMMs) (Fig. 1B). G9a/ (Vav) mice also exhibited efficient
deletion of G9a in lymphoid cells, were born at normal
frequency, and did not display any overt hematological
abnormalities (Lehnertz et al. 2010).
We first investigated the function of G9a-deficient
progenitor cells and evaluated the ability of bone marrow
cells from G9a+/ (Vav) and G9a/ (Vav) mice to form
colonies in cytokine-containing methylcellulose medium.
While no difference in colony-forming unit (CFU) numbers
(Fig. 1C) and phenotypes (Fig. 1D) was observed, the total
cell output of G9a-deficient progenitors was drastically
decreased (Fig. 1E). This was the result of a reduction in the
size of individual colonies, most of which contained <500
cells (Fig. 1F,I).
To assess the activity of G9a-deficient HSCs, we gen-
erated mixed bone marrow chimeras with R26-YFP+-
labeled G9a+/ (Vav) or G9a/ (Vav) cells in competition
with R26-YFP; G9afl/fl cells (Fig. 1H; Supplemental Fig.
S2d). Interestingly, we observed only a modest, non-
significant difference in the relative output of G9a+/ (Vav)
and G9a/ (Vav) cells in the examined lineages 8 wk after
transplantation. (Fig. 1I). However, this trend was no
longer detectable 18 wk after transplantation (Fig. 1J),
suggesting that G9a is not essential for the function of
long-term repopulating HSCs (LT-HSCs).
Loss of G9a impairs AML progression and leukemia
stem cell (LSC) self-renewal in vivo
To investigate G9a function in AML cells, which partially
resemble myeloid progenitors (Krivtsov et al. 2006), we
generated leukemias from knockout and heterozygous
HSPCs by retroviral expression of HoxA9 and Meis1 (A9M)
(Supplemental Fig. S3; Kroon et al. 1998), two genes
frequently overexpressed in human AML (Lawrence
et al. 1999). Importantly, G9a and GLP were expressed in
G9a+/ (Vav); A9M cells, and G9a expression was entirely
ablated in G9a/ (Vav); A9M cells (Fig. 2A). While all
recipients of G9a+/ (Vav); A9M control cells rapidly
advanced to end-stage AML, only 10 of 15 recipients of
G9a/ (Vav); A9M cells succumbed to AML, albeit with
delayed kinetics (median survival 111 d vs. 75 d) (Fig.
2B). In addition, clonal analysis of HoxA9/Meis1 proviral
DNA in the G9a/ (Vav) cohort revealed identical in-
tegration patterns in more than one recipient, indicative
of a reduced repertoire of self-renewing LSC clones (Fig.
2C). To confirm this notion, we performed an in vivo
limiting dilution assay (LDA) using bone marrow cells
harvested from end-stage leukemic mice (Fig. 2D) and
found that the frequency of LSCs among G9a/ (Vav);
A9M cells was reduced ;20-fold (Fig. 2E).
We also generated A9M leukemias from G9afl/fl; Mx-Cre+
mice, allowing the inducible deletion of G9a in vivo
following pIpC treatment (Supplemental Fig. S4a). pIpC
treatment per se had no effect in primary recipients of
G9afl/+ (Mx); A9M cells (Supplemental Fig. S4b). In con-
trast, deletion of G9a in secondary leukemia recipients
of G9afl/fl (Mx); A9M cells led to a dramatic reduction
in circulating leukemic cells after 12 d (Fig. 2E,F) and a
significantly increased median survival of pIpC-treated
mice (44 d vs. 23.5 d) (Fig. 2G). Importantly, G9a de-
ficiency similarly delayed disease progression of MN1-
induced or MLL-AF9-induced experimental AML (Sup-
plemental Fig. S5a,b), suggesting that this enzyme acts
through a general mechanism and plays a role in multi-
ple leukemias.
G9a regulates expansion and differentiation of AML
cells through its methyltransferase activity
We additionally assessed the effects of G9a deletion on
AML cells in vitro. G9a/ (Vav); A9M cells displayed a
substantial growth impairment, with a >2.5-fold increase
in population doubling time (;37 h vs. 14 h), resulting in
a vastly reduced cumulative cell output compared with
controls (Fig. 3A,B). This correlated with significantly
more cells in G1/G0 but no increase in apoptosis (Fig. 3C;
Supplemental Fig. S6). Importantly, loss of p53 did not
rescue this growth deficiency, indicating that a p53-de-
pendent senescence pathway was not responsible for this
phenotype (Fig. 3A). To determine whether the catalytic
activity of G9a was required for efficient AML cell pro-
liferation, we reintroduced wild-type or a methyltransfer-
ase-inactive mutant of G9a (H1166K) into G9a/ (Vav);
A9M cells using an MSCV-ires-GFP (MIG) retroviral
vector (Fig. 3D). Infection with MIG-G9aWT conferred a
competitive growth advantage to transduced (GFP+) over
untransduced (GFP) cells as indicated by their rapid
takeover of the culture. In contrast, control-infected
(empty MIG) and MIG G9aH1166K-infected cells displayed
no growth advantage or even a slight disadvantage, re-
spectively (Fig. 3E,F). Likewise, reintroduction of G9aWT
but not G9aH1166K in G9a/ (Vav); A9M cells restored
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Figure 1. Characterization of G9a-deficient hematopoiesis. (A) Schematic representation of the G9a knockout strategy. Exons 4–20
were flanked by loxP sites to delete the central region of the gene and result in a frameshift in the SET domain coding region. Mice were
routinely genotyped by PCR as shown. (B) Efficient inactivation of the targeted G9a locus in BMMs from G9a/ (Vav) mice. Whole-cell
lysates from BMMs were analyzed by Western blot. The absence of G9a and a characteristic decrease in GLP and H3K9me2 levels were
observed. (C) Normal number of colony-forming cells (CFCs) in G9a/ (Vav) mice. Whole bone marrow cells (2 3 104) were plated in
methylcellulose-based medium containing SCF, IL3, IL6, and Epo. The numbers of colonies at day 8 of culture were comparable
between the G9a/ (Vav) and G9a+/ (Vav) groups. (D) Normal distribution of CFC types in G9a/ (Vav) mice. The relative distribution of
megakaryocyte/erythrocyte (MegE), granulocytic (G), macrophage (M), granulocyte/macrophage (GM), and granulocyte/erythrocyte/
macrophage/megakaryocyte (GEMM) CFCs was assessed in methylcellulose cultures from G9a/ (Vav) and G9a+/ (Vav) bone marrow
cells. No significant differences in the presence of CFUs were detectable in the absence of G9a. (E) Decreased cellular output of G9a-
deficient progenitors. The total cell number of 8-d cultures starting from 2 3 104 G9a/ (Vav) and G9a+/ (Vav) whole bone marrow cells
was assessed. G9a/ (Vav) cultures consistently yielded four to five fewer cells in total and in average per colony. A representative
experiment is shown; n = 4. (F) Representative CFU-GMs of G9a+/ (Vav) and G9a/ (Vav) origin are shown. (G) G9a is required for the
activity of highly proliferative progenitors. G9a+/ (Vav) and G9a/ (Vav) colony sizes were estimated and scored as low (<500 cells),
intermediate (500–5000 cells), and high-proliferative (>5000 cells) categories. Highly proliferative clones are essentially absent in
G9a/ (Vav) bone marrow. (H) Experimental strategy to assess HSC function in the absence of G9a. Bone marrow cells (2 3 106) from
G9a+/ (Vav); R26-YFP+ or G9a/ (Vav); R26-YFP+ test mice were mixed at a 50:50 ratio with YFP competitor (G9afl/fl) bone marrow
cells and transplanted into lethally irradiated congenic CD45.1 hosts. The relative chimerism in recipient mice was assessed by
FACS analysis using YFP fluorescence and lineage-specific surface makers as indicated in Supplemental Figure S2d. (I) Summary of
competitive bone marrow transplantation experiment 8 and 18 wk post-transplant. One representative experiment of two
experiments is shown, individual bone marrow recipients are represented by dots, and significant differences by unpaired t-tests
are indicated. One recipient of G9a/(Vav)/G9afl/fl cells was sacrificed due to dermatitis 10 wk post-transplant.
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Figure 2. G9a deficiency affects AML progression in vivo. (A) Efficient abrogation of G9a expression in G9a/ (Vav) AML cells. 5-FU-
activated G9a+/ (Vav) and G9a/ (Vav) HSPCs were infected with a HoxA9-ires-Meis1 PGK-Neo-expressing MSCV vector and G418-
selected for 5 d in vitro. Whole-cell lysates were analyzed by Western blot. No remaining G9a expression and reduced GLP and
H3K9me2 levels were detectable. Four independent A9M cell lines for each genotype were analyzed. (B) Decreased AML penetrance
and increased disease latency in the absence of G9a. HSPCs of the indicated genotypes were infected with HoxA9/Meis1 as described
above and transplanted at a dose of 5 3 105 cells per irradiated CD45.1 recipient. Proportion of disease-free survival is plotted. (n = 14
for control; n = 15 for knockout cohort); P < 0.0001 using log rank test. (C) Proviral integration patterns in DNA of G9a+/ (Vav) and
G9a/ (Vav) mice suggest that G9a/ (Vav) leukemias contain a limited repertoire of initiating cells. Genomic DNA from bone marrow
cells was digested with SpeI, transferred to a nylon membrane, and hybridized with a Neo probe to detect individual integrants. (D)
G9a/ (Vav) leukemia shows reduction in LSC frequency. Bone marrow cells from leukemic mice shown in A were transplanted at
increasing dilution (105 to 103 cells) in lethally irradiated secondary recipients to assess frequency of LSCs. (Left panel) G9a+/ (Vav)
leukemia was used as control. (Right panel) G9a/ (Vav) leukemia. (E) LDA to estimate LSC frequencies. Survival ratios are listed and
were analyzed using an LDA software (WEHI-ELDA). Estimated LSC frequencies (indicated) decrease 20-fold in the absence of G9a.
(F,G) Requirement for G9a in AML maintenance. Leukemic G9afl/fl (Mx); A9M bone marrow cells (105) from a diseased primary recipient
were transplanted into irradiated secondary recipients. Control mice (G9afl/fl (Mx)) were left untreated, whereas test mice (G9a/ (Mx))
received four injections of pIpC to stimulate Cre expression and abrogate G9a expression. The abundance of peripheral AML cells was
assessed by CD45.2 staining in recipients 12 d after pIpC treatment. G9a inactivation in the G9a/ (Mx) cohort resulted in a significant
decrease of peripheral AML cells. Representative FACS plot is shown in E; statistical summary is shown in F (n = 6 for untreated; n = 7
for treated; P < 0.0001 using unpaired t-test). (H) A significant delay in AML progression in the G9a-depleted cohort (G9a/ (Mx)) was
observed (n = 6 for untreated; n = 7 for treated; P < 0.0001 using log rank test).
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Figure 3. G9a activity determines the proliferation rate of mouse AML cells. (A) Impaired proliferation of AML cells deficient in G9a.
A9M cells of the indicated genotypes were generated as in Figure 2A. The resulting leukemia cell lines were maintained in culture to
assess their growth kinetics. G9a-deficient cultures were characterized by severely reduced proliferation. Compound deletion of p53 did
not rescue this growth defect. Each individual experiment originating from distinct donor bone marrow is represented by a separate curve.
(B) The average population doubling times of cultures from A was calculated and plotted. A >2.5-fold increase in net doubling time was
observed in G9a-deficient cultures. (C) HoxA9/Meis1-expressing G9a/ (Vav) cells display a decrease in cell cycle progression, indicated by
a significant reduction in EdU incorporation compared with G9a+/ (Vav) control cultures. (D) Schematic representation of the used MSCV-
based rescue constructs. A9M cells were infected with either empty MIG retrovirus or MIG-expressing wild-type or mutant G9a. (E,F)
Rescue of G9a/ (Vav); A9M cell growth by wild-type but not methyltransferase-inactive mutant G9aH1166K in vitro. A proliferative
advantage of transduced (GFP+) cells over the remainder of the culture was observed only in G9aWT-infected samples. (G) G9a levels and
activity determine AML disease progression in vivo. G9a+/ (Vav); A9M or G9a/ (Vav); A9M cells were infected with the indicated
retroviruses and transplanted into lethally irradiated recipient mice. Reintroduction of G9aWT into G9a/ (Vav); A9M cells restores
normal AML progression. Ectopic expression of G9aWT in G9a+/ (Vav); A9M cells accelerates AML progression. n = 4 for each group;
significant log rank P-values are indicated. (H) UNC0638-mediated G9a/GLP inhibition recapitulates the G9a/ (Vav) phenotype.
Treatment with 800 nM UNC0638 selectively inhibits the growth of A9M-expressing G9a+/ (Vav) but not G9a/ (Vav) cells,
demonstrating the specificity of this compound. (I) G9a inactivation results in myeloid differentiation of HoxA9/Meis1 leukemic cells.
G9a+/ (Vav) and G9a/ (Vav) were either control-treated (DMSO) or subjected to 1 mM UNC0638 for 5 d. Cytospin preparations indicate
a loss of blast-like morphology and a concomitant increase in myeloid differentiation.
their ability to initiate AML in transplanted recipient
mice (Fig. 3G). Notably, ectopic expression of G9aWT in
G9a+/ (Vav); A9M cells significantly accelerated AML
progression, demonstrating that elevated levels of G9a
increase AML aggressiveness in vivo (Fig. 3G). These
results suggested that catalytic inhibition of G9a should
mimic the phenotype observed in G9a/ (Vav) cells. In-
deed, treatment with the G9a/GLP inhibitor UNC0638
(Vedadi et al. 2011) inhibited the growth of G9a+/ (Vav);
A9M but not G9a/ (Vav); A9M cells in vitro (Fig. 3H).
Furthermore, whereas G9a+/ (Vav); A9M cells exhibited a
characteristic blast-like morphology with a high nucleus
to cytosol ratio and the absence of granular cytosolic
structures, both G9a-deficient and UNC0638-treated
AML cells displayed a significant degree of myeloid dif-
ferentiation (Fig. 3I). Taken together, these results indicate
that the methyltransferase activity of G9a is critical to
maintain high proliferation rates and the incomplete
differentiation characteristic of AML cells.
G9a regulates HoxA9-dependent gene expression
G9a was previously linked to the transforming activity of
Evi-1/Prdm3 (Goyama et al. 2009), a Zn finger containing
H3K9-specific monomethyltransferase (Pinheiro et al.
2012) whose expression is independently correlated with
poor prognosis in AML. Since Evi-1 is critical for the
function of HSCs as well as normal and transformed
progenitors (Goyama et al. 2008), whereas G9a is not
required for HSC function, we thus reasoned that G9a
likely plays important roles independently of its con-
nection with Evi-1. A number of considerations led us to
hypothesize that G9a may exert its role in AML cells by
facilitating HoxA9-dependent gene expression. First,
although HoxA9 plays important roles in HSPCs,
HoxA9-deficient mice are viable and, compared with
Evi-1 mutants, display a relatively mild hematopoietic
phenotype (Lawrence et al. 1997, 2005) that in some
respects resembles that of G9a/ (Vav) mice. Second,
HoxA9 elicits its oncogenic activity in AML cells by
enforcing self-renewal and impairing myeloid differen-
tiation, both of which were affected in G9a/ (Vav) AML
cells. Third, overexpression of wild-type but not cata-
lytically dead G9a accelerates the pathogenesis of HoxA9/
Meis1-driven AML, suggesting that endogenous levels of
G9a are limiting in this model and that it may play a direct
role in HoxA9-regulated transcription mediated through
its methyltransferase activity. To assess this hypothesis,
we first asked whether a physical interaction between
HoxA9 and G9a takes place. To this end, we performed
coimmunoprecipitation studies using Flag- and HA-tagged
versions of G9a and HoxA9, respectively. Indeed, we could
detect a robust interaction between G9a and HoxA9
following immunoprecipitation with anti-Flag or anti-HA
antibodies (Fig. 4A), suggesting that G9a is recruited to
sites of HoxA9-dependent transcription. Next, we in-
vestigated whether the methyltransferase activity of G9a
is required to facilitate HoxA9-dependent gene expression
in mouse AML cells. To this end, we performed microarray
analysis to assess changes in gene expression in HoxA9-
and Meis1-expressing leukemic cells treated with
UNC0638 for 5 d in comparison with mock-treated
controls (Supplemental Fig. S7a). We then compared this
data set to that of a study that used an estrogen receptor-
coupled version of HoxA9 (HoxA9-ER) together with
Meis1 to generate mouse AML cells. These cells were
initially cultured in the presence of 4-hydroxy-tamoxifen
(4OHT) to allow HoxA9 function and then transferred to
medium lacking 4OHT for 5 d prior to measuring
HoxA9-dependent gene expression (Supplemental Fig.
S7b; Huang et al. 2012). Strikingly, gene set enrichment
analysis (GSEA) revealed a highly significant overlap
between genes that responded to UNC0638 treatment in
HoxA9/Meis1 and those that responded to 4OHT with-
drawal in HoxA9-ER/Meis1 cells (Fig. 4B,C). This was
consistent with a decrease in the expression of LSC-
associated genes and an increase in granulocyte-specific
genes in response to UNC0638 or 4OHT withdrawal in
the respective data sets (Supplemental Fig. S7c,d), con-
firming the loss of a self-renewal signature and increased
myeloid differentiation in both of these conditions. To
assess whether the overlap between G9a-dependent and
HoxA9-dependent gene expression changes was due to
a direct effect on HoxA9 target genes or a secondary
effect due to increased differentiation in both condi-
tions, we restricted GSEA only to genes that had been
shown to be bound by HoxA9 in their vicinity and
whose expression either decreased or increased by >1.5-
fold upon 4OHT withdrawal in HoxA9-ER/Meis1-
expressing cells (Huang et al. 2012). Importantly, we
found that HoxA9-occupied genes respond to UNC0638
treatment and HoxA9 withdrawal (by removal of
4OHT) predominantly in the same way and that this
overlap is highly significant in both directions (Fig.
4C,D). Taken together, these data demonstrate that G9a
partakes in the regulation of HoxA9-dependent gene
expression in AML cells, suggesting that the observed
phenotypes in UNC0638-treated AML cells are at least
partially caused by the attenuation of a HoxA9-dependent
gene signature.
Sensitivity to G9A/GLP inhibition is conserved
in human AML specimens
To assess whether G9A inhibition also affects the growth
of human AML cells, we cultured primary human AML
cells (normal karyotype, NPM1wt/FLT3wt) in the presence
or absence of UNC0638 for up to 7 d. Reminiscent of our
observation with murine A9M cells, UNC0638 inhibited
human AML cell proliferation (Fig. 5A–C) and triggered
differentiation. This was evident morphologically (Fig. 5D)
and from an increase in the mast cell surface marker
FceR1a (Fig. 5E). In addition, UNC0638 treatment of
human mobilized CD34+ HSPCs plated in methylcellulose
led to a characteristic reduction in colony size identical to
that observed in murine G9a/ (Vav) progenitor cultures
(Supplemental Fig. S8). To perform a more representative
assessment of G9A’s requirement in human AML pro-
liferation, we tested the response of 15 additional and
genetically diverse primary AML specimens toward
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UNC0646, an improved version of the UNC0638 G9A/
GLP inhibitor (Liu et al. 2011). We detected growth-
suppressive activity of UNC0646 in all tested samples,
albeit to varying degrees, with IC50 values ranging from
0.58 mM to 3.73 mM (Fig. 5F; Supplemental Fig. S9).
Together, these results indicate that our findings in murine
AML models can be extended to humans, demonstrating
that G9A/GLP-dependent methylation is an important
determinant of human AML proliferation.
Discussion
Our data demonstrate that G9a/GLP-dependent methyl-
ation plays an important role in the efficient repression of
terminal differentiation programs in AML and thus for
efficient LSC self-renewal and proliferation. Strikingly,
LSCs exhibit a selective dependency on G9a compared
with normal HSCs. This is consistent with the notion that
oncogenic mutations of IDH1/2 (Mardis et al. 2009) result
in elevated levels of histone marks like H3K9me2 de-
posited by G9A and GLP via inhibition of corresponding
histone demethylases (Lu et al. 2012). Based on the results
presented in this study, it is tempting to speculate that in
an AML context, mutant IDH1/2 might specifically mod-
ulate target gene expression of HOXA9 and/or other tran-
scription factors such as EVI-1, MYB, or MYC, whose roles
in the pathogenesis of AML are at least in part mediated by
G9A. While this would predict a more pronounced sensi-
tivity of IDH1/2 mutant AML cells to inhibitors of G9A/
GLP or other methyltransferases, testing of much larger
cohorts of genetically characterized human AML speci-
mens is necessary to substantiate this hypothesis.
Figure 4. G9a regulates HoxA9-dependent gene expression. (A) Protein–protein interaction between HoxA9 and G9a. Flag-G9a
and HA-HoxA9 were expressed in 293T cells by transient transfection as indicated. Whole-cell extracts from transfected cells (left
panel) or immunoprecipitated material from anti-Flag (middle panel) or anti-HA (right panel) immunoprecipitations were
subjected to Western analysis using anti-Flag or anti-HA antibodies to visualize G9a (top) and HoxA9 (bottom), respectively.
Robust reciprocal interaction between G9a and HoxA9 were detected. (B–E) GSEA plot evaluating changes in gene expression in
A9M cells subjected to 1 mM UNC0638 (5 d). In B, genes that are down-regulated $1.5-fold upon HoxA9 inactivation in Huang
et al. (2012) correlate with control-treated A9M cells and are predominantly down-regulated upon UNC0638 treatment.
Conversely, in C, genes that are up regulated $1.5-fold upon HoxA9 inactivation correlate with genes down-regulated in
UNC0638-treated A9M cells. In D and E, GSEA was restricted to direct targets of HoxA9 according to Huang et al. (2012); i.e.,
genes that were both bound by HoxA9 and changed expression 61.5-fold upon HoxA9 inactivation. (NES) Normalized enrichment
scores; (FDR Q-values) false discovery rate Q-values, indicating the likelihood of an applied gene set with the indicated NES
represents a false-positive finding.
G9a regulates AML growth through HoxA9
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Furthermore, it remains controversial to what extent
global H3K9me2 increases during cellular differentiation
(Wen et al. 2009; Lienert et al. 2011), particularly since
elevated H3K9me2 and H3K9me3 often correlate with the
defective differentiation found in cancerous cells (Lu et al.
2012). This controversy is further spurred by the observa-
tion that G9A/GLP inhibition can help to maintain the
undifferentiated state of human HSCs under ex vivo cul-
ture conditions (Chen et al. 2012). Our data suggest that
the cellular functions of G9a-dependent histone methyla-
tion are highly context-dependent and aid the stabilization
of transcription programs that are specified by develop-
mental transcription factors such as HoxA9 under normal
or malignant circumstances.
From a practical perspective, this study reveals a novel
and specific G9a function that is relevant to human
biology and disease. By showing that G9a/GLP deletion
selectively affects the proliferation of AML cells without
detectable adverse effects on HSC function, our data em-




G9afl mice (Lehnertz et al. 2010), Vav-Cre mice (Stadtfeld and
Graf 2005), and R26-YFP mice (Ye et al. 2003) were described
earlier, and Mx-Cre mice were obtained from Jackson Laboratory.
Figure 5. Sensitivity to G9A inhibition is conserved in human AML cells. (A) Growth inhibition of primary human AML cells in
response to UNC0638 treatment. AML cells (5 3 104; normal karyotype, M1 AML, and NPM1wt/FLT3wt) were plated in the presence of
DMSO or 1 mM UNC0638 and counted after 3 and 7 d. Data represent mean value of four independent cultures for each time point;
error bars represent standard deviations. (B) Clonal human AML growth is inhibited by UNC0638 treatment. AML cells (same as in 4 d)
were plated in methylcellulose-based AML medium and scored after 16 d of culture. Representative colonies are shown. Bar, 1 mm.
(C) UNC0638 treatment resulted in a dramatic decrease of cellular proliferation indicated by an ;10-fold reduction in both total and
per-colony cell numbers. The outcome of 103 cells plated per 2-mL culture is plotted. (D) G9A inhibition causes differentiation of
human AML cells. Primary human AML cells were cultured in liquid cytokine-containing medium in the presence of (1:10,000) DMSO
or 1 mM UNC0638 for 5 d. Representative cytospin preparations are shown, indicating widespread differentiation upon G9A inhibition.
(E) UNC0638 causes up-regulation of FceR1a, indicative of differentiation along the mast cell lineage. (F) UNC0646 exhibits growth-
suppressive activity across different subclasses of human AML. Diagnostic AML samples (n = 15) were treated with UNC0646 for 5 d in
a threefold serial dilution setup. IC50 values were calculated relative to DMSO control-treated samples and are plotted. Error bars
represent 95% confidence intervals. Additional information on genotypes and dose response curves of the respective samples are
provided in Supplemental Figure S9.
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All strains were maintained on a pure C57/B6 background and
used between 6 and 12 wk of age. All procedures were conform
with institutional guidelines.
Antibodies for Western analysis
Antibodies used for Western analysis were anti-G9a (clone
A8620A, R&D Systems; clone C6H3, Cell Signaling Technology),
anti-GLP (clone B0422, R&D Systems), anti-H3H9me2 (ab1220,
Abcam), anti-H3 (ab1791, Abcam; clone C6H3, Cell Signaling
Technology), anti-Flag (clone M2, Sigma-Aldrich), and anti-HA
(clone 12CA5, Roche Applied Science).
Progenitor growth assay
Bone marrow cells were plated at 2 3 104 cells per milliliter
culture. Methylcellulose medium (M3434, Stem Cell Technolo-
gies) was either purchased or generated in-house. CFUs were
scored at day 8 after plating.
Competitive bone marrow transplantation experiments
Bone marrow cells from age- and sex-matched mice were mixed
1:1 with YFP control (G9afl/fl) bone marrow cells. We trans-
planted 4 3 106 cells into lethally irradiated CD45.1 hosts. After
8 and 18 wk, we determined the ratios of YFP-negative (G9afl/fl)
versus YFP-positive (G9a+/ (Vav) or G9a/ (Vav)) cells in donor-
derived (CD45.2+) granulocytes (Gr1+, Mac1+), monocytes (Gr1,
Mac1+), T cells (CD3+), and B cells (B220+) using standard FACS
antibodies on a BD LSRII.
Bone marrow cell transduction and generation of mouse
AML models
MSCV HoxA9-ires-Meis PGK-Neo construct was obtained from
Mark Kamps (University of California at San Diego). Retroviral
infections were essentially done as described (Thorsteinsdottir
et al. 2002). A9M-expressing cells were selected with 1.2 mg/mL
G418 and injected into lethally irradiated CD45.1 mice. Re-
cipients were monitored daily and sacrificed at humane AML
endpoints according to institutional policy. For in vitro
experiments, A9M cells were cultured in mouse AML culture
medium (DMEM, 15%FBS, 100 ng/mL rmSCF, 10 ng/mL rmIL-3,
10 ng/mL rhIL-6, L-glutamine, penicillin/streptomycin, 1/100,000
b-mercaptoethanol; cytokines purchased from Stem Cell Tech-
nologies) at a plating density of 5 3 104 to 2 3 105 cells per
milliliter.
Secondary AML transplantation experiments
Leukemic bone marrow cells from diseased primary recipient
mice were extracted, cryopreserved, and then transplanted into
sublethally irradiated secondary recipient mice. Mx-Cre+ AML
cells were induced with four intraperitoneal injections of pIpC
(400 mg; Sigma) at days 3, 5, 7, and 9 after transplantation unless
indicated otherwise.
Immunoprecipitation studies
HEK293T cells were subcultured at 60% confluence on 100-
mm dishes and transfected with the indicated plasmids using
Lipofectamine 2000 transfection reagent (Invitrogen). Forty-
eight hours post-transfection, cells were rinsed twice with
ice-cold PBS and incubated with RIPA lysis buffer (Santa Cruz
Biotechnology). Fifteen microliters of Protein-A/G beads was
added to the cell lysates for 30 min at 4°C for preclearing. Five-
hundred micrograms of precleared protein was incubated with
4.0 mg of indicated antibodies overnight at 4°C, followed by
adding 20 mL of Protein-A/G beads. After a 3-h incubation, the
beads were precipitated, washed once with RIPA buffer and
twice with PBS, and boiled in 23 loading dye. Samples were
separated by 10% SDS-PAGE and transferred to nitrocellulose
membrane (Bio-Rad Laboratories). Blots were incubated with
the indicated antibodies and visualized using the Odyssey
infrared system (LI-COR Biosciences).
Human AML cells
All human AML samples used in these studies were collected by
the Quebec Leukemia Cell Bank (BCLQ) with the informed
consent and approval of the Leucegene project by the research
ethics board of the Maisonneuve-Rosemont Hospital and Univer-
sité de Montréal. Cryopreserved AML cells were thawed and
cultured in serum-free conditions in the presence of SR1 (Alichem,
catalog no. 41864) and UM729 (Sauvageau 2013). UNC0638/
UNC0646 were added to growth medium from a 5 mM DMSO
stock solution.
Gene expression and statistical analyses
G9a-dependent gene expression was assessed by comparing
DMSO- and UNC0638-treated A9M cells (800 nM, 5 d, three
biological replicates per condition). RNA was extracted with
Trizol and analyzed on Affimetrix Mouse Gene 1.0 chip (acces-
sible on Gene Expression Omnibus [GEO], GSE53894). HoxA9-
dependent gene expression files (Affymetrix Mouse Genome 430
2.0 chip) (Huang et al. 2012) were downloaded from GEO
(GSE21299). CEL files were processed using the ExpressionFile-
Creator (RMA method) and PreprocessDataSet modules in the
Genepattern suite (Broad Institute). GSEA analysis was done using
log2 transformed expression values and the ‘‘difference of classes’’
setting with the provided gene sets (Supplemental Table 1). All
further statistical analyses were done using Flowjo (Treestar) and
Graphpad Prism.
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